 BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. Nasdaq: BCTX, BCTXW TSX-V:BCT BriaCell or the Company, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival OS data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCells lead candidate Bria-IMTTM as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab KEYTRUDA; manufactured by Merck Co., Inc. and Incytes retifanlimab manufactured and provided under a corporate collaboration with Incyte Corporation. 